Blog Layout

PCOR-ANZ Annual Report 2023: Improving Prostate Cancer Care

Judith Clarke • Jun 06, 2024

Unveiling the latest PCOR-ANZ  report: A Journey Through Prostate Cancer Care Evolution

We are thrilled to announce the release of the PCOR-ANZ Annual Report 2023: “Prostate Cancer Across Australia and New Zealand PCOR-ANZ 2015-2021.” This comprehensive report is dedicated to improving clinical standards and patient outcomes in prostate cancer care through extensive data collection and analysis captured within the PCOR-ANZ registry.


  • see highlights below, and read full report here

    Key Highlights Relevant to Aotearoa New Zealand:


    ·        Completeness of Data Collection: 100 % public cases; over 80% new diagnoses
    ·        Low access to MRI pre-biopsy and targeted biopsy techniques in Aotearoa
    ·        Higher percentage of low-risk disease diagnosed, high cost and low value
    ·        High percentage of low-risk disease managed through Active Surveillance

    Registry Overview:

    ·        The Australian and New Zealand Prostate Cancer Outcomes Registry (PCOR-ANZ) is a Movember-funded clinical registry.
    ·        Findings are based on data from 92,167 newly diagnosed individuals with prostate cancer, spanning 2015 to 2021.
    ·        Data collected from 268 clinical sites and 396 clinicians across Australia and New Zealand.
    ·        Impressive population coverage: Approximately 59% in Australia and 80% in New Zealand.

    Transformative Trends:

    Throughout the reporting period, the landscape of prostate cancer management across NCCN risk groups has undergone remarkable transformations, mirroring the strides made in international guidelines and recommendations. Two such transformative trends outlined in the report are:

    A shift towards Active Surveillance for Low-Risk Prostate Cancer:  Proportion of individuals opting for active surveillance increased from 66% (2015) to 80% (2021).
    Management of Prostate Cancer with Regional Involvement: Utilisation of radiation therapy alongside androgen deprivation therapy (ADT) increased from 33% (2015) to 52% (2021).

    These trends reflect an evolving landscape where emerging technologies and therapeutic strategies enhance patient outcomes. The PCOR-ANZ remains uniquely positioned to monitor and evaluate these care practices.

Explore the Full Report here

By Judith Clarke 15 Aug, 2024
Big news: Eng Toh has secured a $30,000 Health Research Council activation grant to examine ethnic inequities alongside other factors affecting positive surgical margin rates in men with Prostate cancer
By Judith Clarke 07 Feb, 2024
Deep dive into inequities in NZ Prostate Cancer diagnosis, treatment and quality of life begins
07 Aug, 2023
Stephen Mark (PCOR-NZ Clinical Lead) gratefully accepts a donation for $130K of funds raised by the Bike For Blokes charity!
Share by: